This is a pipeline-expansion press release with long timeframes (HDV Phase 2 still 6+ months away; PBC/PSC Phase 2 >12 months away). The news is modestly positive for the scientific thesis but does not change near-term valuation. Monitor for HDV Phase 2 data in Q4 2026 as the next hard catalyst.
Price Chart
Executive Summary
Assembly Bio is expanding ABI-6250, an oral NTCP inhibitor in Phase 1a for HDV, into cholestatic liver diseases (PBC/PSC) with a targeted Phase 2 basket study in Q1 2027. While this broadens the pipeline into a large unmet-need market (PSC has no approved therapies), the program is pre-clinical for these indications with no safety/efficacy data yet. The company's HDV Phase 2 is still slated for Q4 2026. No financial data, partner updates, or near-term catalysts were provided.
Key Facts
- ABI-6250 (NTCP inhibitor) expansion into PBC and PSC, with Phase 2 basket study expected Q1 2027
- Existing Phase 1a completed in healthy volunteers, showing target engagement (dose-dependent bile acid elevations)
- HDV Phase 2 study still on track for Q4 2026
- Pre-IND meeting with FDA held for cholestatic liver disease program; minutes pending but company calls it constructive
- PSC has zero approved therapies; PBC has multiple treatments but high rate of inadequate response
- No new financial data, partner updates (Gilead collab), or changes to cash runway disclosed
Financial Impact
Pre-revenue clinical-stage biotech; no financial metrics disclosed. Pipeline expansion adds optionality but no near-term revenue or cost data.
Risk Factors
- ABI-6250 has not been approved anywhere and has no clinical efficacy data in cholestatic diseases
- Phase 2 in PBC/PSC not yet initiated; regulatory feedback pending from FDA meeting minutes
- Company may require additional capital to fund expanded pipeline — cash position not disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300036 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $30.01 $35.28 | ▲ +17.56% | ▲ +18.75% | $20.30 (−32.36%) |
Aug 13, 2026 10w ago | Press Release | $32.95 $34.38 | ▲ +4.34% | ▲ +5.71% | $20.30 (−38.39%) |
Jun 11, 2026 19w ago | Institutional Cluster | $22.53 $24.15 | ▲ +7.19% | ▲ +6.76% | $20.30 (−9.90%) |
Jun 5, 2026 20w ago | 8-K | $22.56 $23.34 | ▲ +3.48% | ▲ +1.37% | $20.30 (−10.00%) |
May 22, 2026 22w ago | 424B5 | $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $20.30 (+29.39%) |
May 22, 2026 22w ago | 8-K | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 22, 2026 22w ago | Press Release | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 7, 2026 24w ago | Press Release | $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $20.30 (−31.74%) |
Mar 30, 2026 30w ago | EFFECT | $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $20.30 (−23.80%) |
Mar 19, 2026 31w ago | Press Release | $28.46 $27.70 | ▼ −2.67% | ▼ −0.52% | $20.30 (−28.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers